MST continus 5 mg tablets
*Company:
Mundipharma Pharmaceuticals Limited - Formerly Napp LaboratoriesStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 28 November 2024
File name
ie-spc-mst-continus-5mg-clean.pdf
Reasons for updating
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.9 Overdose
Toxic leukoencephalopathy has been observed with morphine overdose.
10. DATE OF (PARTIAL) REVISION OF THE TEXT
27th November 2024
Updated on 28 November 2024
File name
ie-pl-mst-continus-clean.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Removal of one or more presentations from joint PIL
Free text change information supplied by the pharmaceutical company
Updates are done in below sections:
2. What you need to know before you take MST Continus tablets
MST Continus tablets contain lactose and Sunset Yellow (E110)
The 5 mg, 10 mg, 15 mg, and 30 mg and 60 mg tablets contain lactose which is a form of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking these tablets.
The 30 mg and 60 mg tablets contain Sunset yellow (E110) which may cause allergic reactions.
3. How to take MST Continus tablets
If you take more MST Continus tablets than you should
Call your doctor or hospital straight away as you may need emergency treatment in hospital. People who have taken an overdose may feel very sleepy, sick, dizzy, get a brain disorder (known as toxic leukoencephalopathy) or get pneumonia from inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever). People who have taken an overdose may also have breathing difficulties leading to unconsciousness, or even death. When seeking medical attention make sure that you take this leaflet and any remaining tablets with you to show to the doctor.
6. Contents of the pack and other information
What MST Continus tablets contain
The active ingredient is morphine sulfate. Each tablet contains 5 mg, 10 mg, 15 mg, 30 mg, 60 mg or 100 mg of morphine sulfate.
The tablets also contain the following colourants:
10 mg – Iron oxide (E172)
15 mg - Iron oxide (E172), brilliant blue (E133), quinoline yellow (E104) and indigo carmine (E132)
30 mg – Erythrosine (E127), indigo carmine (E132) and sunset yellow (E110)
60 mg - Erythrosine (E127), quinoline yellow (E104) and sunset yellow (E110)
100 mg - Iron oxide (E172) and indigo carmine (E132)
What MST Continus tablets look like and the contents of the pack
MST Continus tablets are marked with NAPP on one side and the strength (e.g. 5 mg, 10 mg, etc) on the other.
The tablets are film-coated in the following colours: 5 mg - white, 10 mg – golden brown, 15 mg - green, 30 mg – purple, 60 mg - orange, 100 mg – grey.
This leaflet was last revised in March November 2024.
Updated on 06 November 2024
File name
Patient Leaflet-PIL-IE-MST continus-clean.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Removal of one or more presentations from joint PIL
Free text change information supplied by the pharmaceutical company
Removal of 60 mg strength from common PIL due to withdrawal application.
Updated on 28 May 2024
File name
IE_MST continus_PIL (Clean)-v4[IE Reporting].pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 28 May 2024
File name
IE_MST continus_5mg_SmPC (Clean).pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 29 March 2023
File name
mst continus-smpc-5mg-clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
IE MAH Address Change
Updated on 29 March 2023
File name
mst continus-pil-clean.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
IE MAH Address Change